Pfizer gains ground in cholesterol antibody chase
Pfizer has put on a late spurt in the race to bring a PCSK9 blocker class to market, reporting positive phase 2b data for bococizumab, which has now entered late-stage testing. Results from the 24-week study show that bococizumab (RN316) was significantly better than placebo in reducing elevated LDL-cholesterol, a major risk factor for cardiovascular [...]
